Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF

Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy

The Egyptian Journal of Internal Medicine volume 29, pages 77–82 (2017)Cite this article

Abstract

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency disease (PID) among adults. CVID consists of two phenotypes—one in which infections are the characteristic and another in which impressive inflammatory and/or hematological complications also develop, including lymphadenopathy, splenomegaly, autoimmune cytopenias, enteropathy, and granulomatous disease. These phenotypes appear to be stable, are related to immunological and inflammatory markers, and are predictive of outcomes. Both subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG) are equally effective for replacement therapy. No data are available about specific factors affecting the quality of life related to switching from IVIG to SCIG in the Arabian Gulf area. We present the case reports of three adult CVID patients, who were shifted from IVIG to SCIG by the US conversion method (1 : 1.5). We followed-up patients for clinical outcomes, side-effects, immunoglobulin G (IgG) trough levels, annual infection rate, and quality of life using questionnaires (RAND-36) over a 3-year period. Three patients (two females and one male), with a mean age of 26 years, had received IVIG [Gamunex-C (Grifols Therapeutics Inc., NC, 27709 USA) 10%; Grifols] treatment for an average duration of 4 years and had average IgG trough levels of 7.7±2.9 g/dl. Patients were shifted to SCIG [Subcuvia (Baxalta Innovation GmbH, Vienna, Austria) 10%; Baxter] for different reasons. SCIG was administered, using an infusion pump, under medical supervision at the hospital, on a weekly basis. The average IgG trough level on SCIG was 10.4±1.5 g/dl. The annual infection rate of pneumonias, sinusitis, otitis media, and others significantly declined after switching to SCIG in all three patients. However, while on IVIG treatment, some patients reported headache and malaise, but when on the SCIG treatment the reactions were mild and infusion site-related such as erythema, swelling, and itching. Remarkably, all patients were successfully switched to SCIG with significant decrease in the annual rate of infections and a favorable steady-state of serum trough levels of IgG. The use of SCIG was generally associated with notable improvement in physical, emotional, and social health.

References

  1. Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, et al. International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007; 120:776–794.

    PubMed  Google Scholar 

  2. Bousfiha A, Picard C, Boisson-Dupuis S, Zhang SY, Bustamante J, Puel A, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol 2010; 135:204–209.

    Article  CAS  Google Scholar 

  3. Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H,Conley E, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 2009; 124:1161–1178.

    Article  CAS  Google Scholar 

  4. Borte S, Janzi M, Pan-Hammarstrom Q, von Dobeln U, Nordvall L, Winiarski J, et al. Placental transfer of maternally-derived IgA precludes the use of guthrie card eluates as a screening tool for primary immunodeficiency diseases. PLoS One 2012; 7:e43419.

  5. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2011; 2:54.

    Article  Google Scholar 

  6. Borte M, Bernatowska E, Ochs HD, Roifman CM. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol 2011; 164:357–364.

    Article  CAS  Google Scholar 

  7. Jolles S. The variable in common variable immunodeficiency: a disease of complex phenotypes. Allergy Clin Immunol Pract 2013; 1:545–556.

    Article  Google Scholar 

  8. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277–286.

    Article  CAS  Google Scholar 

  9. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119:1650–1657.

    Article  CAS  Google Scholar 

  10. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94–100.

    Article  CAS  Google Scholar 

  11. Jolles S, Orange J, Gardulf A, Stein M, Shapiro R, Borte M, Berger M. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol 2015; 179:146–160.

    Article  CAS  Google Scholar 

  12. De Gracia J, Vendrell M, Alvarez A, Pallisa E, Rodrigo MJ, de la Rosa D, et al. Immunoglobulin therapytocontrol lung damage inpatients with common variable immunodeficiency. Int Immunopharmacol 2004; 4:745–753.

    Article  Google Scholar 

  13. Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012; 169:172–181.

    Article  CAS  Google Scholar 

  14. Yong PL, Boyle J, Ballow M, Boyle M, Berger M, Bleesing J, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010; 135:255–263.

    Article  CAS  Google Scholar 

  15. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117(4 Suppl): S525–S553.

  16. Oliveira JB, Fleisher TA. Laboratory evaluation of primaryimmunodeficiencies. J Allergy Clin Immunol 2010; 125:S297–S305.

  17. Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency. Transfus Med Rev 2010; 24(Suppl 1):S28–S50.

  18. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Hsu JT, et al. American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology: Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94(Suppl 1):S1–63.

  19. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747–755.

    Article  CAS  Google Scholar 

  20. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin for infectious diseases: back to the preantibiotic and passive prophylaxis era? Trends Pharmacol Sci 2004; 25:306–310.

    Article  CAS  Google Scholar 

  21. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H, Zinkernagel RM. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999; 286:2156–2159.

    Article  CAS  Google Scholar 

  22. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Kwon YD, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.Science 2010; 329:811–817.

  23. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26:265–273.

    Article  CAS  Google Scholar 

  24. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995; 345:365–369.

    Article  CAS  Google Scholar 

  25. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, et al. Rapid subcutaneous IgG replacement therapy is effective and safein children and adults with primary immunodeficiencies—aprospective, multi-national study. J Clin Immunol 2006; 26:177–185.

    Article  CAS  Google Scholar 

  26. Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338:162–166.

    Article  CAS  Google Scholar 

  27. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004; 112:1–7.

    Article  CAS  Google Scholar 

  28. Toubi E, Etzioni A. Intravenous immunoglobulin in immunodeficiency states: state of the art. Clin Rev Allergy Immunol 2006; 29:167–172.

    Article  Google Scholar 

  29. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008; 28:779–802.

    Article  Google Scholar 

  30. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007; 21:105–116.

    Article  CAS  Google Scholar 

  31. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multinational study. J Clin Immunol 2006; 26:177–185.

    Article  CAS  Google Scholar 

  32. Abrahamsen TG, Sandersen H, Bustnes A Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics. 1996; 98(Pt 1):1127–1131.

  33. Bhole MV, Burton J, Chapel HM. Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy. Immunol Allergy Clin North Am 2008; 28:821–832.

    Article  Google Scholar 

  34. Hernando M, Palacin P, Nalda N, Arenas M, Boren T, et al. Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain. An Pediatr (Barc) 2009; 70:111–119.

    Article  Google Scholar 

  35. Fadeyi M, Tran T. Calculating the dose of subcutaneous immunoglobulin for primary immunodeficiency disease in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coefficient. P T 2013; 38:768–770.

    PubMed  PubMed Central  Google Scholar 

  36. Daly PB, Evans JH, Kobayashi RH, Kobayashi AL, Ochs HD, Fischer SH, et al. Home-based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy 1991; 67:504–510.

    CAS  PubMed  Google Scholar 

  37. Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2004; 93:160–165.

    Article  CAS  Google Scholar 

  38. Gardulf A, Borte M, Ochs HD, Nicolay U Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008; 126:81–88.

    Article  CAS  Google Scholar 

  39. Winkelstein JA, Conley ME, James C, Howard V, Boyle J. Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore) 2008; 87:253–258.

    Article  Google Scholar 

  40. Quinti I, Di Pietro C, Martini H, Pesce A, Lombardi F, et al. Health related quality of life in common variable immunodeficiency. Yonsei Med J 2012 53:603–610.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, Faculty of Medicine, Kuwait University, 24923, Safat, Kuwait City, 13110, Kuwait

    Mona Al-Ahmad MBBCh, FRCPC

  2. Immunology Unit, Department of Allergy, Al-Rashed Allergy Center, Kuwait City, Kuwait

    Mona Al-Ahmad MBBCh, FRCPC, Ahmed Maher & Jasmina Nurkic

Authors
  1. Mona Al-Ahmad MBBCh, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed Maher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jasmina Nurkic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mona Al-Ahmad MBBCh, FRCPC.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al-Ahmad, M., Maher, A. & Nurkic, J. Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy. Egypt J Intern Med 29, 77–82 (2017). https://doi.org/10.4103/ejim.ejim_2_17

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_2_17

Keywords